- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 129-143 of
153 results
1022 Exhibit: Ex 1022 Plaintiffs First Amended Complaint from Amarin Pharma, Inc...
Document
IPR2022-00215, No. 1022 Exhibit - Ex 1022 Plaintiffs First Amended Complaint from Amarin Pharma, Inc et al vs Hikma Pharms USA Inc et al, CA No 20 1630 D Del DI17 (P.T.A.B. Nov. 30, 2021...
|
|
Cite Document
1036 Exhibit: Ex 1036 Scheduling Order from Amarin Pharma, Inc et al vs Hikma Ph...
Document
IPR2022-00215, No. 1036 Exhibit - Ex 1036 Scheduling Order from Amarin Pharma, Inc et al vs Hikma Pharms USA Inc et al, CA No 20 1630 D Del (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1039 Exhibit: Ex 1039 Original Japanese version of WO 2007142118 to Yokoyama...
Document
IPR2022-00215, No. 1039 Exhibit - Ex 1039 Original Japanese version of WO 2007142118 to Yokoyama et al (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1007 Exhibit: Ex 1007 Grimsgaard et al, Highly Purified Eicosapentaenoic Acid and...
Document
IPR2022-00215, No. 1007 Exhibit - Ex 1007 Grimsgaard et al, Highly Purified Eicosapentaenoic Acid and Docosahexaenoic Acid in Humans Have Similar Triacylglycerol Lowering Effects but Div...
|
|
Cite Document
1006 Exhibit: Ex 1006 Satoh et al, Purified Eicosapentaenoic Acid Reduces Small D...
Document
IPR2022-00215, No. 1006 Exhibit - Ex 1006 Satoh et al, Purified Eicosapentaenoic Acid Reduces Small Dense LDL, Remnant Lipoprotein Particles, and C Reactive Protein in Metabolic Syndrom...
|
|
Cite Document
1003 Exhibit: Ex 1003 WO 2007142118 to Yokoyama et al 2007 certified English tra...
Document
IPR2022-00215, No. 1003 Exhibit - Ex 1003 WO 2007142118 to Yokoyama et al 2007 certified English translation (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1004 Exhibit: Ex 1004 Mori et al, Purified Eicosapentaenoic and Docosahexaenoic...
Document
IPR2022-00215, No. 1004 Exhibit - Ex 1004 Mori et al, Purified Eicosapentaenoic and Docosahexaenoic Acids Have Differential Effects on Serum Lipids and Lipoproteins, LDL Particle Size, Glu...
|
|
Cite Document
1002 Exhibit: Ex 1002 Expert Declaration of Edward A Fisher, MD, PhD, MPH
Document
IPR2022-00215, No. 1002 Exhibit - Ex 1002 Expert Declaration of Edward A Fisher, MD, PhD, MPH (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1012 Exhibit: Ex 1012 Schmidt et al, Lipid evaluation in HIV 1 positive patients treat...
Document
IPR2022-00215, No. 1012 Exhibit - Ex 1012 Schmidt et al, Lipid evaluation in HIV 1 positive patients treated with protease inhibitors, 4 Antiviral Ther 163 170 1999 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1008 Exhibit: Ex 1008 Third Report of the National Cholesterol Education Program ...
Document
IPR2022-00215, No. 1008-3 Exhibit - Ex 1008 Third Report of the National Cholesterol Education Program N CEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholestero...
|
|
Cite Document
1013 Exhibit: Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 4
Document
IPR2022-00215, No. 1013-4 Exhibit - Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 4 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1013 Exhibit: Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 13
Document
IPR2022-00215, No. 1013-13 Exhibit - Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 13 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1040 Exhibit: Ex 1040 US Patent No 6,384,077 to Peet et al
Document
IPR2022-00215, No. 1040 Exhibit - Ex 1040 US Patent No 6,384,077 to Peet et al (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1032 Exhibit: Ex 1032 Notice of Allowability from US Patent Office re US Patent App...
Document
IPR2022-00215, No. 1032 Exhibit - Ex 1032 Notice of Allowability from US Patent Office re US Patent Application No 13614,111 Feb 11, 2013 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1019 Exhibit: Ex 1019 Plaintiffs Validity Contentions from Amarin Pharma, Inc v Hik...
Document
IPR2022-00215, No. 1019 Exhibit - Ex 1019 Plaintiffs Validity Contentions from Amarin Pharma, Inc v Hikma Pharms USA Inc, No 16 2525 D Nev Part 1 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
